Page 41 - Primary Biliary Cholangitis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primary biliary cholangitis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primary Biliary Cholangitis Today - Breaking & Trending Today

New research has helped unravel the role of a key molecule in cholestatic liver disease

Researchers from the Quadram Institute, University of East Anglia and Technische Universität Braunschweig found that, in mice, a key metabolic regulator triggers cells in the immune system to attack liver cells, progressing the disease. ....

Stuart Rushworth , Stuarta Rushworth , Technische Universita , Anna Isaacs , Karsten Hiller , Tobias Ludwig , Federico Bernuzzi , Naiara Beraza , Charlotte Hellmich , Andre Martens , Mar Moreno Gonzalez , Quadram Institute , Norwich Research Park , University Of East Anglia , Sciences Research Council , Norwich Medical School , Research Council , Doctoral Training Partnership , East Anglia , Norwich Research , Medical School , Prof Dr Karsten Hiller , Molecular Gastroenterology , Biological Sciences Research Council , Medical Research Council , Anna Isaacs Ten ,

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership . | December 17, 2021 ....

France General , United States , Hong Kong , United Kingdom , Fanny Allaire , Pascal Prigent , Jess Smith , David Loew , Ipsen Euronext , Stephanie Boyer , Global Communications , European Commission , Drug Administration , Terns Pharmaceuticals , Head Of Global Communications , European Medicines Agency , Globenewswire Inc , Business Development , Primary Biliary Cholangitis , Breakthrough Therapy Designation , Orphan Drug Designation , Medicines Agency , Chief Executive Officer , Breakthrough Therapy , Rare Disease , Total Sales ,

Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

Agreement gives Ipsen global rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational ....

France General , United States , Hong Kong , United Kingdom , Fanny Allaire , Pascal Prigent , Jess Smith , David Loew , Ipsen Euronext , Global Communications , European Commission , Uncertainties Of The Company , Drug Administration , Terns Pharmaceuticals , Exchange Commission , Head Of Global Communications , European Medicines Agency , Stephanie Boyer , Business Development , Primary Biliary Cholangitis , Breakthrough Therapy Designation , Orphan Drug Designation , Chief Executive Officer , Biliary Cholangitis , Breakthrough Therapy , Rare Disease ,

Ipsen gets rights to failed Genfit NASH drug, now in Phase 3 for rare liver disease

Ipsen is paying €120 million up front to acquire global rights to elafibranor, a Genfit drug that fell short as a treatment for NASH, but is currently in Phase 3 testing in another liver disease, primary biliary cholangitis. Meanwhile, Genfit is adding an early-stage drug candidate to its own pipeline via a separate transaction. ....

France General , David Loew , Genoscience Pharma , Intercept Pharmaceuticals , Ironwood Pharmaceuticals , Cymabay Therapeutics , Weight Loss , Medical Devices , Healthcare Innovation , Medcity News , Medcity News , San Francisco , Life Sciences , Rock Health , Startup Advice , Startup Funding , Patient Monitoring System , Otion Sensors , Healthcare It , Foodborne Pathogens , Iagnostics Company , Iagnostic Platforms , Minimally Invasive Surgery , Aser Surgery , Ealth And Wellness , Mployee Wellness Programs ,